Noerr advised Catalio Capital Management LP on the deal. ATAI Life Sciences, a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, announced…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Federica Tiefenthaler
…
This content is for Standard 1 Year members only. LoginJoin Now